Based on the central role of SphK1 in NEPC development, small molecule‐specific inhibitors can overcome Enzalutamide resistance as well as tumor growth of several clinically relevant NEPC models and decrease NE biomarkers in PDE. This evidence concerns the gene SPHK1 and neoplasm.